Single‐dose immunisation with a multimerised SARS‐CoV‐2 receptor binding domain (RBD) induces an enhanced and protective response in mice
暂无分享,去创建一个
Jordan J. Clark | J. Stewart | J. Löwe | L. James | A. Kipar | A. R. Aricescu | J. Hiscox | M. Vaysburd | A. Owen | Parul Sharma | V. Chang | Ralf Salzer | Anna Albecka | L. Kiss | A. Gonzalez Llamazares | A. Aricescu
[1] Rachel L. Spreng,et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses , 2021, Nature.
[2] Jiecan Zhou,et al. The Mechanisms and Animal Models of SARS-CoV-2 Infection , 2021, Frontiers in Cell and Developmental Biology.
[3] Andrew L. Phillips,et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[4] A. Ward,et al. One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization , 2021, bioRxiv.
[5] D. Ho,et al. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates , 2021, bioRxiv.
[6] Laura E. Crowell,et al. Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters , 2021, bioRxiv.
[7] I. Wilson,et al. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates , 2021, Science Advances.
[8] Baoying Huang,et al. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice , 2021, Cellular & molecular immunology.
[9] Stephanie S. Chen,et al. Emergence of a Novel SARS-CoV-2 Variant in Southern California. , 2021, JAMA.
[10] R. Fåhraeus,et al. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages , 2021, Biomolecules.
[11] Elisabeth Mahase. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant , 2021, BMJ.
[12] K. Kupferschmidt. New mutations raise specter of 'immune escape'. , 2021, Science.
[13] M. Nussenzweig,et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice , 2020, Science.
[14] Jonathan L. Schmid-Burgk,et al. COVID-19 Bibliometrics 8 th – 14 th February 2021 , 2021 .
[15] W. Chiu,et al. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice , 2021, ACS central science.
[16] Carl A. B. Pearson,et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.
[17] D. Qu,et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response , 2020, Signal Transduction and Targeted Therapy.
[18] Xin He,et al. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses , 2020, Immunity.
[19] Elisabeth Mahase. Covid-19: What do we know about the late stage vaccine candidates? , 2020, BMJ.
[20] J. Pollet,et al. Recombinant protein vaccines, a proven approach against coronavirus pandemics , 2020, Advanced Drug Delivery Reviews.
[21] S. Perlman,et al. COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.
[22] D. Schneidman-Duhovny,et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 , 2020, Science.
[23] S. Ladhani,et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection , 2020, bioRxiv.
[24] Lisa E. Gralinski,et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 , 2020, Cell.
[25] L. Zentilin,et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology , 2020, EBioMedicine.
[26] H. Rammensee,et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.
[27] K. Sauer,et al. An Effective COVID-19 Vaccine Needs to Engage T Cells , 2020, Frontiers in Immunology.
[28] E. Aronica,et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study , 2020, The Lancet Microbe.
[29] R. Owens,et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses , 2020, Nature Communications.
[30] D. Irvine,et al. Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo , 2020, Immunity.
[31] Ralf Bartenschlager,et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.
[32] T. Solomon,et al. Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays , 2020, The Journal of infectious diseases.
[33] S. Munro,et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion , 2020, bioRxiv.
[34] Shuwen Liu,et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.
[35] Zeyu Chen,et al. T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.
[36] Yuquan Wei,et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.
[37] D. Matthews,et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein , 2020, Genome Medicine.
[38] S. Klein,et al. Considering how biological sex impacts immune responses and COVID-19 outcomes , 2020, Nature Reviews Immunology.
[39] M. Malim,et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings , 2020, medRxiv.
[40] S. Klein,et al. Biological sex impacts COVID-19 outcomes , 2020, PLoS pathogens.
[41] L. Stamatatos,et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual , 2020, bioRxiv.
[42] S. Klein,et al. Clinical trials for COVID-19 should include sex as a variable. , 2020, The Journal of clinical investigation.
[43] Fang Li,et al. Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[44] Jiajia Xie,et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein , 2020, Biochemical and Biophysical Research Communications.
[45] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[46] D. Cucinotta,et al. WHO Declares COVID-19 a Pandemic , 2020, Acta bio-medica : Atenei Parmensis.
[47] M. Pal,et al. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update , 2020, Cureus.
[48] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[49] D. Stuart,et al. Lentiviral transduction of mammalian cells for fast, scalable and high-level production of soluble and membrane proteins , 2018, Nature Protocols.
[50] J. Andersen,et al. TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination , 2018, Proceedings of the National Academy of Sciences.
[51] M. Howarth,et al. Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination , 2018, ACS nano.
[52] Karl D. Brune,et al. New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue , 2018, Front. Immunol..
[53] David Baker,et al. Design of a hyperstable 60-subunit protein icosahedron , 2016, Nature.
[54] D. Klenerman,et al. Initiation of T cell signaling by CD45 segregation at ‘close-contacts’ , 2016, Nature Immunology.
[55] B. Zakeri,et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin , 2012, Proceedings of the National Academy of Sciences.
[56] Weixian Lu,et al. A time- and cost-efficient system for high-level protein production in mammalian cells. , 2006, Acta crystallographica. Section D, Biological crystallography.
[57] B. Wiedenheft,et al. Structure of the DPS-like protein from Sulfolobus solfataricus reveals a bacterioferritin-like dimetal binding site within a DPS-like dodecameric assembly. , 2006, Biochemistry.
[58] J. Morecroft,et al. Radionuclide ejection fraction , 1988, The British journal of surgery.
[59] S. Davis,et al. Glycan Remodeling with Processing Inhibitors and Lectin-Resistant Eukaryotic Cells. , 2015, Methods in molecular biology.